| 000 | 01794 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516193949.0 | ||
| 264 | 0 | _c20160803 | |
| 008 | 201608s 0 0 eng d | ||
| 022 | _a1537-453X | ||
| 024 | 7 |
_a10.1097/COC.0000000000000036 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, Grace J | |
| 245 | 0 | 0 |
_aThe Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cApr 2016 |
||
| 300 |
_a136-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xmortality |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xmortality |
| 650 | 0 | 4 |
_aChemoradiotherapy _xmethods |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xmortality |
| 650 | 0 | 4 | _aEsophagectomy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoadjuvant Therapy |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xdrug therapy |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aTaxoids _xadministration & dosage |
| 700 | 1 | _aKoshy, Matthew | |
| 700 | 1 | _aHanlon, Alexandra L | |
| 700 | 1 | _aHoriba, M Naomi | |
| 700 | 1 | _aEdelman, Martin J | |
| 700 | 1 | _aBurrows, Whitney M | |
| 700 | 1 | _aBattafarano, Richard J | |
| 700 | 1 | _aSuntharalingam, Mohan | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 39 _gno. 2 _gp. 136-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/COC.0000000000000036 _zAvailable from publisher's website |
| 999 |
_c23507809 _d23507809 |
||